Właściwości i oznaczanie substancji o działaniu psychoaktywnym

• Autorzy: Jakubowska I. , Choma J.

Warianty tytułu

EN

Properties and detection of ‘designer drugs’

• Języki publikacji: PL

Abstrakty

PL

W artykule opisano substancje o działaniu psychoaktywnym działające na ośrodkowy układ nerwowy. Są to związki lub też mieszaniny związków syntetycznych (m.in. BZP - N benzylopiperazyna, mefedron, JWH-018 (naftalen-1-yl-(1-pentyloindol-3-yl)metanon), TFMPP - trifluorometylofenylo-piperazyna) oraz naturalne mieszanki zioł i roślin (np. szałwia wieszcza, kratom, muchomor czerwony, kava-kava itp.). Przedstawiono ich działanie i wpływ na ludzi zażywających je sporadycznie oraz regularnie. Ponadto opisano niebezpieczeństwa związane z zażywaniem tych środków. Przedstawiono przykładowe metody analizy. W tym celu wykorzystywana jest chromatografia cienkowarstwowa, jako metoda przygotowawcza połączona zwykle z ekstrakcją i stosowana zazwyczaj do oczyszczenia próbek. Przytoczono przykłady zastosowania chromatografii gazowej i cieczowej, jako głównych metod analizy substancji o działaniu psychoaktywnym.

EN

The paper describes psychoactive substances acting on the central nervous system, commonly referred to as designer drugs. Designer drugs are compounds or mixtures of synthetic compounds (e.g. BZP - N-benzylpiperazine, mephedrone, JWH-018 (naphthalen-1-yl-(1-pentyloindol-3-yl)-methanone), TFMPP -trifluoromethylpiperazine) and natural blend of herbs and plants (e.g. sage poet, kratom, fly agaric, kava-kava, etc.). Their effects are presented, the impact on the people using them occasionally or regularly describes the hazards associated with the use of these funds. Analysis methods, based mainly on chromatographic methods, are also presented. Thin-layer chromatography, as a preparatory method, usually combined with extraction is used for samples purification. Application of gas chromatography and liquid chromatography as main methods of analysis is shown.

Słowa kluczowe

PL

substancje o działaniu psychoaktywnym; właściwości substancji; metody analizy

EN

designer drugs; drugs properties; analytical methods

• Wydawca: Wojskowa Akademia Techniczna im. Jarosława Dąbrowskiego
• Czasopismo: Biuletyn Wojskowej Akademii Technicznej
• Rocznik: 2013
• Tom: Vol. 62, nr 2
• Strony: 123--143
• Opis fizyczny: Bibliogr. 52 poz., rys., wykr.

Twórcy

autor

Jakubowska I.

• Wojskowa Akademia Techniczna, Wydział Nowych Technologii i Chemii, Instytut Chemii, 00-908 Warszawa, ul. gen. S. Kaliskiego 2

autor

Choma J.

• Wojskowa Akademia Techniczna, Wydział Nowych Technologii i Chemii, Instytut Chemii, 00-908 Warszawa, ul. gen. S. Kaliskiego 2

Bibliografia

• [1] Ustawa o przeciwdziałaniu narkomanii (Dz.U. z 2012 r. poz. 124. Tekst jednolity obowiązujący od 9 czerwca 2012 r.).
• [2] M. M. Aung, G. Griffin, J. W. Huffman, M. J. Wu, C. Keel, B. Yang, V. M. Showalter, M. E. A bood, B. R. Martin, Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding, Drug Alcohol Depen., 60, 2000, 133-140.
• [3] V. Auwärter, S. Dresen, W. Weinmann, M. Müller, M. Pütz, N. Ferreirós, ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?, J. Mass Spectrom., 44, 2009, 832 837.
• [4] I. Vardakou, C. Pistos, C. Spiliopoulou, Spice drug as a new trend: mode of action, identification and legislation. Toxicol. Lett., 197, 2010, 157-162.
• [5] J.W. Huffman, P. V. Szklennik, A. Almond, K. Bushell, D. E. Selley, H. He, M. P. Cassidy, J. L. Wiley, B. R. Martin, 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles., Bioorg. Med. Chem. Lett., 15, 2005, 4110-4113.
• [6] W. A. Devane, A. Breuer, T. Sheskin, T. U. C. Jaerbe, M. S. Eisen, R. Mechoulam, A novel probe for the cannabinoid receptor, J. Med. Chem., 35, 1992, 2065-2069.
• [7] Europol-EMCDDA, Joint Report on a new psychoactive substance: 4-methylmethcathinone (mephedrone), European Monitoring Centre for Drugs and Drug Addiction, 27 May 2010, retrieved 2011-01-29.
• [8] A. Winstock, L. Mitcheson, P. Deluca, Z. Davey, O. Corazza, F. Schifano, Mephedrone, new kid for the chop?, Addiction, 106, 2010, 154-161.
• [9] A. G. Budzynski, N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’), Neuropsychopharmacology, 30, 2005, 550-560.
• [10] D. M. Wood, J. Button, S. Lidder, J. Ramsey, D. W. Holt, P. I. Dargan, Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP), J. Med. Toxicol., 4, 2008, 254-257.
• [11] M. Alansari, D. Hamilton, Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report, N Z Med. J., 119, 2006, 1233.
• [12] W. Arunotayanun, S. Gibbons, Natural product ‘legal highs’, Nat. Prod. Rep., 29, 2012, 1304 1316.
• [13] J. C. Lin, R. K. Jan, H. Lee, M. A. Jensen, R. R. Kydd, B. R. Russell, Determining the subjective and physiological effects of BZP combined with TFMPP in human males, Psychopharmacology, 3, 2011, 761-768.
• [14] J. M. Hooker, Y. Xu, W. Schiffer, Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans, Neuroimage, 41, 2008, 1044-1050.
• [15] P. Przekop, T. Lee, Persistent psychosis associated with salvia divinorum use, Am. J. Psychiatry, 166, 2009, 832-832.
• [16] O. Grundmann, S.M. Phipps, I. Zadezensky, V. Butterweck, Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology, Planta Med., 73, 2007, 1039-1046.
• [17] W. Wacławik, M. Strzałka, Z. Janeczko, Rośliny psychoaktywne z rodziny Lamiaceae, Farmacja Pol., 61, 2005, 467-480.
• [18] C. E. Groer, K. Tidgewell, R. A. Moyer, W. W. Harding, R. B. Rothman, T. E. Prisinzano, L. M. Bohn, An opioid agonist that does not induce micro-opioid receptor-arrestin interactions or receptor internalization, Mol. Pharmacol., 71, 2007, 549-557.
• [19] M. Brvar, M. Mozina, M. Bunc, Prolonged psychosis after Amanita muscaria ingestion, Wien. Klin. Wochenschr., 118, 2006, 294-297.
• [20] L. Satora, D. Pach, B. Butryn, P. Hydzik, B. Balicka-Slusarczyk, Fly agaric (Amanita muscaria) poisoning, case report and review, Toxicon, 45, 2005, 941-943.
• [21] D. R. Benjamin, Mushrooms: poisons and panaceas - a handbook for naturalists, mycologists and physicians, New York: WH Freeman and Company, 1995.
• [22] A. Letcher, Shroom: A Cultural history of the magic mushroom, London: Faber and Faber, 2006.
• [23] P. Waser, Chemistry and pharmacology of muscarine, muscarone and some related compounds, Pharmacology Department, University of Zurich, Switzerland, 1961.
• [24] D. Michelot, L. M. Melendez-Howell, Amanita muscaria: chemistry, biology, toxicology, and ethnomycology, Mycol. Res., 107, 2003, 131-146.
• [25] G. A. Johnston, D. R.Curtis, W. C. De Groat, A.W. Duggan, Central actions of ibotenic acid and muscimol, Biochem. Pharmacol., 17, 1968, 2488-2489.
• [26] J. Ott, Pharmanopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine, J. Psychoactive Drugs, 33, 2001, 273-281.
• [27] E. Macko J. Weisbach, B. Douglas, Some observations on the pharmacology of mitragynine, Arch. Int. Pharmacodyn. Ther., 198, 1972, 145-161.
• [28] H. Takayama, Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa, Chem. Pharm. Bull., 52, 2004, 916-928.
• [29] H. Takayama, H. Ishikawa, M. Kurihara, M. Kitajima, N. Aimi, D. Ponglux, F. Koyama, K. M atsumoto, T. Moriyama, L.T. Yamamoto, K. Watanabe, T. Murayama, S. Horie, Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands, J. Med. Chem., 45, 2002, 1949-1956.
• [30] K. M. Babu, C. R. Mccurdy, E. W. Boyer, Opioid receptors and legal highs: Salvia divinorum and Kratom, Clin. Toxicol., 46, 2008, 146-152.
• [31] E. W. Boyer, J. M. Chao, A. H. Marderosian, Ergoline alkaloidal constituents of Hawaiian baby wood rose, Argyreia nervosa (Burm. f.), J. Pharm. Sci., 62, 1973, 588-591.
• [32] M. Borsutzky, T. Passie, W. Paetzold, H. M. Emrich, U. Schneider, Hawaiian baby woodrose: (Psycho-) Pharmacological effects of the seeds of Argyreia nervosa. A case-orientated demonstration, Nervenarzt, 73, 2002, 892-896.
• [33] C. Göpel, A. Maras, M. H. Schmidt, Hawaiian baby rose wood: case report of an argyreia nervosa induced toxic psychosis, Psychiatr. Prax., 30, 2003, 223-224.
• [34] L. Mayagoitia, J. L. Diaz, C. M. Contreras, Psychopharmacologic analysis of an alleged oneirogenic plant: Calea zacatechichi, J. Ethnopharmacol., 18, 1986, 229-243.
• [35] V. Maphosa, P. Masika, A. Adedapo, Safety evaluation of the aqueous extract of Leonotis leonurus shoots in rats, Hum. Exp. Toxicol., 27, 2008, 837-843.
• [36] E. W. Boyer, P. T. Lapen, G. Macalino, P. L. Hibberd, Dissemination of psychoactive substance information by innovative drug users, CyberPsychology and Behavior, 10, 2007, 1-6.
• [37] P. P. Fu, Q. Xia, L. Guo, Toxicity of Kava kava, J. Environ. Sci. Health [C], 26, 2008, 89-112.
• [38] R. Metzner, Ayahuasca: Hallucinogens, Consciousness, and the Spirit of Nature, New York: Thunder’s Mouth, 1999.
• [39] C. Ratsch, The Encyclopedia of Psychoactive Plants, Rochester, Vt.: Park Street, 2005.
• [40] D. J. Mckenna, G. H. N. Towers, F. Abbott, Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca, J. Ethnopharmacol., 10, 1984, 195-223.
• [41] R. J. Trassman, C. R. Qualls, Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects, Arch. Gen. Psychiatry, 51, 1994, 85 97.
• [42] J. J. Vepsalainen, S. Auriola, M. Tukiainen, N. Ropponen, J.C. Callaway, Isolation and characterization of yuremamine, a new phytoindole, Planta Med., 71, 2005, 1053-2057.
• [43] A. Yuruktumen, S. Karaduman, F. Bengi, J. Fowler, Syrian rue tea: a recipe for disaster, Clin. Toxicol., 46, 2008, 749-752.
• [44] L. Farouk, A. Laroubi, R. Aboufatima, R. Benharref, A. Chait, Evaluation of the analgesic effect of alkaloid extract of Peganum harmala L.: possible mechanisms inved, J. Ethnopharmacol., 12, 2008, 449-454.
• [45] J. H. Kennedy, J. M. Wiseman, Direct analysis of Salvia divinorum leaves for salvinorin A by thin layer chromatography and desorption electrospray ionization multi-stage tandem mass spectrometry, Rapid Commun. Mass Spectrom., 24, 2010, 1305-1311.
• [46] A. R. Bilia, L. Scalise, M. C. Bergonzi, F.F . Vincieri, Analysis of kavalactones from Piper methysticum (kava-kava), J. Chromatogr. B, 812, 2004, 203-214.
• [47] S. P. Vorce, M. J. Holler, B. Tevine, M. R. Pas, Detection of 1-Benzylpiperazine and 1-(3-Trifluoromethylphenyl)-piperazine in Urine. Analysis Specimens Using GC-MS and LC-ESI MS, J. Anal. Toxicol., 32, 2008, 442-450.
• [48] H. Tsutsumi, M. Katagi, A. Miki, N. Shima, T. Kamata, M. Nishikawa, K. Nakajima, H. Tsuchihashi, Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3 trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine, J. Chromatogr. B, 819, 2005, 315-322.
• [49] N. Uchiyama, R. Kikura-Hanajiri, M. Kawamura, Y. Goda, Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products, Forensic Toxicol., 29, 2011, 25-37.
• [50] J. W. Huffman, P. V. Szklennik, A. Almond, K. Bushell, D. E. Selley, H. He, M. P. Cassidy, J. L. Wiley, B. R. Martin, 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles, Bioorg. Med. Chem. Lett., 15, 2005, 4110-4113.
• [51] A. P. Salum Pires, C. Dizioli Rodrigues De Oliveira, S. Moura, F. A. Dörr, W. E. Silva, M. Yonamine, Gas chromatographic analysis of dimethyltryptamine and b-carboline alkaloids in Ayahuasca, an Amazonian Psychoactive Plant Beverage, Phytochem. Anal., 20, 2009, 149-153.
• [52] C. Gambelunghe, K. Aroni, R. Rossi, L. Moretti, M. Bacci, Identification of N,N-dimethyltryptamine and β-carbolines in psychotropic ayahuasca beverage, Biomed. Chromatogr., 10, 2008, 1056-1059.